SCHEMBL12316320

SCHEMBL12316320

CNc1ccc(C(N)=O)c(O)c1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.57
▸ ALDH1A1 P00352 4/20 0.57
▸ GLA P06280 1/20 0.57
▸ GAA P10253 1/20 0.57
▸ FABP3 P05413 1/20 0.40
▸ FABP4 P15090 1/20 0.40
▸ FABP5 Q01469 1/20 0.40
▸ NNMT P40261 1/20 0.39
▸ MAP2K3 P46734 1/20 0.39
▸ MAPK14 Q16539 1/20 0.39
▸ ERN1 O75460 1/20 0.38
▸ CLCN2 P51788 1/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ ATM Q13315 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ PRKCI P41743 1/20 0.35
▸ KDM4C Q9H3R0 1/20 0.35
▸ IKBKB O14920 1/20 0.35
▸ HPGD P15428 2/20 0.34
▸ MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8856841 0.76 KDM4E (0.54) KDM4EALDH1A1GLAGAAFABP3
SCHEMBL5860264 0.76 IDO1 (0.40) KDM4EALDH1A1GLAGAAFABP3
SCHEMBL11735266 0.75 KMT2A (0.52) KDM4EALDH1A1GLAGAAERN1
SCHEMBL19183435 0.75 KDM4E (0.45) KDM4EALDH1A1ERN1KMT2AATM
SCHEMBL12316307 0.74 CA1 (0.49) RAB9A
SCHEMBL12316432 0.73 ERN1 (0.42) KDM4EALDH1A1GLAGAAERN1
SCHEMBL8857062 0.73 ALDH1A1 (0.50) KDM4EALDH1A1GLAGAAFABP3
SCHEMBL5649788 0.73 ALDH1A1 (1.00) KDM4EALDH1A1GLAGAANNMT
SCHEMBL7169725 0.73 KDM4E (0.74) KDM4EALDH1A1GLAGAANNMT
SCHEMBL27824412 0.72 KDM4E (0.53) KDM4EALDH1A1GLAGAANNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263592-B2 Equilibrative nucleoside transporter ENT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2012-09-11 — — US disclosed
US-8263592-B2 Equilibrative nucleoside transporter ENT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2012-09-11 — — US disclosed
US-20100280025-A1 EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-11-04 — — US disclosed
US-20100280025-A1 EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-11-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280025-A1 EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS SLC29A1, SLC29A2, SLC43A3 KDM4E 4733/4885ALDH1A1 516/4885GLA 4181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback